Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (131-140 of 188) with videos related to

Pageof 19
Sort By:
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Haematologica|March 17, 2022
Treatment emergent peripheral neuropathy in the CASSIOPEIA trialCathelijne Fokkema, Phillipe Moreau, Bronno Van der Holt, et al.
Hemasphere|August 29, 2025
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma NetworkGrigoris Gerotziafas, Despina Fotiou, Inger Nijhof, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
European Journal of Haematology|March 4, 2011
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaMichel Delforge, Evangelos Terpos, Paul G Richardson, et al.
The Oncologist|March 29, 2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Future Oncology (London, England)|May 3, 2023
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Niels Wcj van de Donk, Hareth Nahi, et al.
Advances in Therapy|August 6, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple MyelomaCyrille Touzeau, Brea Lipe, Abdullah M Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
The New England Journal of Medicine|May 11, 2012
Continuous lenalidomide treatment for newly diagnosed multiple myelomaAntonio Palumbo, Roman Hajek, Michel Delforge, et al.
Pageof 19

Showing results (131-140 of 188) with videos related to

Sort By:
Pageof 19
The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.
Haematologica|March 17, 2022
Treatment emergent peripheral neuropathy in the CASSIOPEIA trialCathelijne Fokkema, Phillipe Moreau, Bronno Van der Holt, et al.
Hemasphere|August 29, 2025
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma NetworkGrigoris Gerotziafas, Despina Fotiou, Inger Nijhof, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
European Journal of Haematology|March 4, 2011
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myelomaMichel Delforge, Evangelos Terpos, Paul G Richardson, et al.
The Oncologist|March 29, 2011
Multiple myeloma treatment strategies with novel agents in 2011: a European perspectiveHeinz Ludwig, Meral Beksac, Joan Bladé, et al.
Future Oncology (London, England)|May 3, 2023
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Niels Wcj van de Donk, Hareth Nahi, et al.
Advances in Therapy|August 6, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple MyelomaCyrille Touzeau, Brea Lipe, Abdullah M Khan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
The New England Journal of Medicine|May 11, 2012
Continuous lenalidomide treatment for newly diagnosed multiple myelomaAntonio Palumbo, Roman Hajek, Michel Delforge, et al.
Pageof 19